SRI‐37330 impaired thioredoxin‐interacting protein (TXNIP) function in pancreas, which in turn impaired glucagon secretion from the alpha cells, contributed to lower blood glucose levels.[89] Unlike glucagon receptor antagonists, SRI‐37330 did not have any lipogenic effect.[90] In fact, if anything, SRI‐37330 reversed hepatic fat accumulation, facilitating its potential use in treatment of type 2 diabetes and fatty liver disease. The gene discussed is GCG; the disease is type 2 diabetes mellitus.